Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ath – page 10

1 642 clinical trials in Ath, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ath at a glance
1 642
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 642 trials in Ath

Open in trial search

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

Phase 2 Randomized Trial of Oral NS-863 in Patients with Pulmonary Arterial Hypertension

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NS-863
  • Sponsor:Ns Pharma Inc.

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

IgA nephropathy

Recruiting

Study of ARGX-121 to Reduce Proteinuria in Adults with Primary IgA Nephropathy (IgAN)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ARGX-121
  • Sponsor:Argenx

Study of ZL-1310, BI 764532 and atezolizumab in patients with advanced small cell lung cancer and neuroendocrine tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

Neoplasm

Recruiting

Phase 2 Study Evaluating Safety and Efficacy of Belzutifan in Adults with Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

A Phase 3 Study of Once‑Daily Treprostinil Palmitil Inhalation Powder for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ath

What the registry says about research in the country

01 Cardiovascular and Cerebrovascular Research

Clinical research in Ath addresses critical cardiovascular conditions, particularly focusing on cerebrovascular events. Investigations center on acute ischemic stroke and high-risk transient ischemic attack, conditions that represent significant causes of disability and mortality. These studies aim to evaluate novel therapeutic approaches designed to reduce the risk of recurrent ischemic events in patients who have experienced these serious cerebrovascular incidents.

  • Assessment of innovative pharmacological interventions for stroke prevention
  • Evaluation of treatment strategies to minimize recurrent cerebrovascular events
  • Investigation of therapeutic efficacy in acute cerebrovascular conditions
  • Research focused on improving outcomes for patients with transient ischemic attacks

The research underway seeks to establish safer and more effective treatment protocols for individuals at elevated risk of stroke, potentially improving long-term neurological outcomes and quality of life for affected patients.

02 Oncology and Gastrointestinal Cancer Research

Ath hosts clinical investigations in the field of oncology, with particular emphasis on gastrointestinal malignancies. Research efforts concentrate on locally advanced rectal cancer, examining treatment strategies tailored to specific patient populations. These trials explore different approaches to neoadjuvant therapy, which involves treatment administered before surgical intervention, aiming to optimize the balance between treatment effectiveness and patient safety.

  • Comparison of conventional neoadjuvant therapy versus total neoadjuvant therapy approaches
  • Evaluation of treatment efficacy and safety profiles in older cancer populations
  • Investigation of optimal timing and sequencing of chemotherapy and radiation therapy
  • Research on personalized treatment strategies for rectal cancer management

These studies are particularly significant as they address the unique needs of older patients with rectal cancer, seeking to identify treatment regimens that maximize therapeutic benefit while minimizing adverse effects in this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.